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Background: An understanding of the activated protein signaling 
architecture in non–small-cell lung cancer (NSCLC) is of critical 
importance to the development of new therapeutic approaches and 
identification of predictive and prognostic biomarkers for patient 
stratification.
Methods: We used reverse-phase protein microarrays to map the 
activated protein signaling networks of 47 NSCLC tumors, 28 of 
which were node negative, which were subjected to tumor cellular 
enrichment using laser capture microdissection. The phosphoryla-
tion/cleavage levels of 111 key signaling proteins and total levels of 
17 proteins were measured for broadscale signaling analysis.
Results: Pathway activation mapping of NSCLC revealed distinct 
subgroups composed of epidermal growth factor receptor (ERBB1), 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3), 
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ERBB4), 
v-akt murine thymoma viral oncogene homolog 1- mammalian target 
of rapamycin (AKT-mTOR), protein kinase, AMP-activated, alpha 2 
catalytic subunit (AMPK), and autophagy-related signaling, along 
with transforming growth factor-beta-signaling protein 1 (SMAD), 
insulin-line growth factor receptor (IGFR), rearranged during trans-
fection proto-oncogene (RET), and activated CDC42-associated 
kinase (ACK)  activation. Investigation of epidermal growth fac-
tor receptor (EGFR)-driven signaling identified a unique cohort of 
tumors with low EGFR protein expression yet high relative levels of 
phosphorylated EGFR and high EGFR total protein with low relative 
levels of phosphorylation. Last, mapping analysis of patients with 
NSCLC with N0 disease revealed a pilot pathway activation signature 
composed of linked epidermal growth factor receptor family (HER)-
AMPK-AKT-mTOR signaling network along with focal adhesion 
kinase- LIM domain kinase-1 (FAK-LIMK) and janus kinase (JAK)-
signal transducers and activators of transcription (STAT) pathways 
that correlated with short-term survival and aggressive disease.
Conclusions: Functional protein pathway activation mapping of 
NSCLC reveals distinct activation subgroups that are underpinned by 
important therapeutic targets and that patients with early-stage node 
negative disease and poor prognosis may be identified by activation 
of defined, biochemically linked protein signaling events. Such find-
ings, if confirmed in larger study sets, could help select and stratify 
patients for personalized targeted therapies.
Key Words: Cell signaling, Protein pathway activation mapping, 
Reverse-phase protein microarrays, Non–small-cell lung cancer.
(J Thorac Oncol. 2012;7: 1755–1766)
Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.1 In 2004, lung cancer 
caused 20% of all cancer-related deaths in Europe and 29% 
in the United States.2,3 Lung tumors are routinely classified 
in two major histological subtypes: small-cell lung carci-
noma (SCLC) and non–small-cell lung carcinoma (NSCLC), 
and NSCLC accounts for approximately 85% of all cases of 
lung cancer. The majority of NSCLC is further divided into 
squamous-cell carcinoma, adenocarcinoma , and large-cell 
carcinoma.4 Adenocarcinoma has become the most prevalent 
subtype of NSCLC in recent decades.5,6 Although early-stage 
lung cancer has a higher 5-year survival, the prognosis of stage 
I lung cancer is highly variable. Postoperative recurrence of 
stage I NSCLC leads to an early mortality rate of approxi-
mately 40%,7 and current clinical pathology techniques can-
not distinguish stage I patients into long-term (survivors) and 
short-term survival (fatality) groups.
Numerous studies have used genomic-based approaches 
to better characterize the molecular underpinnings of 
NSCLC and develop new taxonomical means to describe the 
disease.8–11 Although there have been some recent attempts to 
use novel discovery-based proteomic approaches for NSCLC 
cell line studies12–14 and limited protein signaling analysis 
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of clinical material by us and others,15,16 there is yet to be 
a systematic broadscale analysis of the functional protein 
signaling architecture of NSCLC clinical samples and of 
aggressive early-stage disease. A deeper understanding of the 
ongoing functional protein signaling events within the tumor 
is of critical importance because protein-expression levels 
cannot mostly be predicted by gene transcript expression,17–19 
and protein signaling events mediated principally by 
phosphorylation-driven posttranslational modifications are 
modulated by ongoing kinase activities that are at the nexus 
of molecularly targeted inhibitors that now comprise a large 
portion of the current oncology drug pipeline.
A specific kinase-driven pathway that has well-known 
significance in lung cancer is the epidermal growth factor 
receptor (EGFR) family signaling network. Overexpression of 
EGFR has been observed in 40% to 80% of the NSCLC,20–22 
which is often associated with aggressive clinical behaviors, 
such as advanced stage, increased metastatic rate, higher 
tumor proliferation rate, and poor prognosis.23–25 EGFR over-
expression in NSCLC provided a rationale to develop EGFR 
tyrosine kinase inhibitors (TKIs) that block either receptor 
extracellular domains or the intracellular kinase activity, and a 
number of these TKIs have been cleared by the United States 
Food and Drug Administration for treatment of advanced or 
metastatic NSCLC.26–30
The observation that certain subgroups of patients, par-
ticularly female patients, nonsmokers, East Asians, or patients 
with lung adenocarcinoma, have a higher response rate and 
clinical benefit with certain targeted therapies, motivated 
researchers to elucidate the molecular mechanism responsible 
for this increased response.31–34 Recent findings have revealed 
a positive relationship between the presence of activating 
mutations in the EGFR tyrosine kinase domain and clini-
cal response.31–34 These somatic mutations cause constitutive 
activation of the EGFR tyrosine kinase by destabilizing its 
autoinhibited conformation, which is normally maintained in 
the absence of ligand stimulation.35 However, most of those 
patients with mutational portraits that predict best response 
to EGFR TKIs usually relapse and become resistant to further 
treatment with these inhibitors.36–41 Thus, although most of the 
clinical research on EGFR has been focused on receptor over-
expression and gene mutation profiling/status, only recently 
have we begun to understand the relationships between EGFR 
phosphorylation patterns in lung cancer tissue, relationships 
between EGFR mutations and EGFR phosphorylation levels 
at defined sites, and an understanding of which EGFR phos-
phorylation sites are activated in individual patient tumors.15,42
In the current study, we analyzed the activated (phosphor-
ylated) protein signaling architecture in laser capture microdis-
sected (LCM) NSCLC epithelial cells from individual biopsy 
specimens using reverse phase protein microarray (RPMA) to 
interrogate over a hundred key signaling proteins in patients 
with node-negative and node-positive disease. The goals of this 
study were to use a functional signal pathway activation map-
ping approach to develop a pilot NSCLC signaling taxonomy 
knowledge base, a deeper understanding of EGFR signaling 
architecture, and to determine whether there were protein sig-
naling network activation events that could be found in early-
stage N0 disease that correlated with an aggressive phenotype.
MATERIALS AND METHODS
NSCLC Tissue Study Set
The study population consisted of 47 fully informed 
patients (36 men and 11 women; mean age 66 years; range, 
43–83), who underwent surgery for lung NSCLC at Clinica 
Chirurgica 2, Padova, Italy, between 1993 and 2005. Twenty-
seven of the tumors were adenocarcinoma and 20 were squa-
mous carcinoma. According to TNM (tumor, node, metastasis) 
staging system, 24 (51%) were classified T1, 20 (42.5%) T2, 
and 3 (6.5%) T3; 28 (59.6%) were N0, 14 (29.8%) were N1, 
4 (8.5%) were N2, and 1 (2.1%) Nx. The histological grade 
was assessed according to World Health Organization crite-
ria: 7 tumors (14.9%) were well differentiated, 25 (53.2%) 
moderately differentiated, 11 (23.4%) poorly differentiated, 
and in 4 tumors (8.5%), histological grade was not available 
(Table 1). All specimens were snap-frozen in liquid nitrogen 
within 5 minutes of surgical removal to preserve molecular 
information and stored at −80°C for the entire duration. None 
of the patients underwent preoperative chemotherapy or radio-
therapy, and all tumor specimens were obtained before any 
therapy from treatment-naive patients.
Laser Capture Microdissection and RPMA
Highly enriched (>95%) tumor epithelium cell popula-
tions were obtained using LCM as described previously.43,44 
Approximately 20,000 cells, taken from several tissue sections 
to ensure tumor coverage and control for cellular heterogeni-
ety, were procured for each patient sample. Pathway activation 
mapping was performed by reverse-phase protein microrray 
(RPMA) as previously described.15,45–47 In brief, LCM procured 
tumor epithelia were subjected to lysis with 2.5% solution of 
2-mercaptoethanol (Sigma, St. Louis, MO) in Tissue Protein 
Extraction Reagent (t-PERTM Pierce)/2× sodium dodecyl sul-
fate Tris-Glycine 2× sodium dodecyl sulfate buffer (Invitrogen, 
Carlsbad, CA). The lysates were printed on glass-backed 
nitrocellulose array slides (Schott, Louisville, KY) using an 
Aushon 2470 arrayer (Aushon BioSystems, Burlington, MA) 
equipped with 185 µm pins. Each primary NSCLC lysate was 
printed in triplicate. Arrays were blocked (I-Block, Applied 
BioSystems, Foster City, CA) for 1 hour and subsequently 
probed with 128 phosphorylated, cleaved or total protein anti-
bodies. Detection was performed using a fluorescence-based 
tyramide signal amplification strategy using Streptavidin-
conjugated IRDye680 (LI-COR Biosciences, Lincoln, NE) 
as detection reagent. All antibodies were validated for single 
band specificity and for ligand induction (for phospho-specific 
antibodies) by Western blotting before use on the arrays, as 
described previously.47 Each array was scanned using a Vidar 
scanner (Vidar Systems Corporation, Herndon, VA). After 
scanning, spot intensity was analyzed, data were normalized to 
total protein, and a standardized, single data value was gener-
ated for each sample on the array by MicroVigene software 
V2.999 (VigeneTech, North Billerica, MA). A full list of all 
128 signaling proteins (including total protein/phosphopro-
tein and cleaved proteins) is shown in Supplementary Table 1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A346). Protein signaling analytes were chosen for analysis 
based on their previously described involvement in key aspects 
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of tumorigenesis: growth, survival, autophagy, apoptosis, dif-
ferentiation, adhesion, motility, and inflammation.
EGFR Mutational Analysis
Mutation status of EGFR kinase domain (exons 18–21) 
was assessed for each tissue sample. DNA was directly 
extracted from 10-mm frozen sections by using Maxwell 16 
Tissue DNA Purification Kit (Promega Corporation, Madison, 
WI) according to the manufacturer’s instruction. Amplification 
of exons 18–21 and fragments sequencing were accomplished 
using primer sequences previously described.29,32 Polymerase 
chain reaction (PCR) was executed with Phusion High-
Fidelity DNA Polymerases (Finnzymes, Espoo, Finland) with 
an annealing temperature of 58°C. Amplified fragments were 
purified using MultiScreen PCR
m96
 Plate (EMD Millipore, 
Billerica, MA) according to the manufacturer’s instruction. 
Purified PCR products were sequenced by using Big Dye 
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) 
to determine the presence or absence of EGFR mutations. 
Cycle sequencing reactions were performed in 96-well for-
mat at 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds, 
60°C for 4 minutes. Sequencing reactions were precipitated 
using Montage SEQ
96
 Sequencing Reaction Cleanup kit 
(EMD Millipore, Billerica, MA) heated 3 minutes at 96°C 
and analyzed with ABI PRISM 3100 Genetic Analyzer with 
the Sequencing Analysis software (Applied Biosystems).
Statistical Analysis
The continuous variable RPMA data generated were 
subjected to both unsupervised and supervised statistical 
analysis. Statistical analyses were performed on final RPMA 
intensity values obtained using SAS version 9 software 
(supervised analysis) or JMP v5.0 (SAS Institute, Cary, NC) 
(for unsupervised clustering analysis). For unsupervised two-
way hierarchical clustering, we used the Ward method in JMP. 
Subgroup cuttings were chosen based on distance plots (shown 
in bottom right of the heatmaps shown) whereby a rapid rise in 
the centroid distance defined the cutting point. For supervised 
analysis, initially, the distribution of variables was checked. 
If the distribution of variables for the analyzed groups (e.g., 
primary versus metastasis or metastatic versus nonmetastatic) 
was normal, a two-sample t test was performed. If the variances 
of two groups were equal, two-sample t test with a pooled 
variance procedure was used to compare the means of intensity 
between two groups. Otherwise, two-sample t test without a 
pooled variance procedure was adopted. For non-normally 
distributed variables, the Wilcoxon rank sum test was used. All 
significance levels were set at a p value less than 0.05. Hazard 
ratios of Cox proportional hazard model were calculated using 
R version 2.9.2 software (The R Foundation for Statistical 
Computing). Hazard ratio h of one variable v1 to another 
variable v2 means the rate of progression to death of v1 is h 
times that of v2. p Value of χ2 test tests the null hypothesis that 
the coefficient of a variable is equal to zero. If the p value for 
the test is less than 0.05, the null hypothesis is rejected, and this 
variable, such as pathway signature, sex, age, grade, or stage, is 
significantly related to survival time. Kaplan–Meier (log-rank) 
survival estimates were used for univariate survival analysis.
RESULTS
Protein Pathway Activation Mapping of NSCLC
Unsupervised hierarchical clustering analysis (Fig. 1) 
revealed the presence of five different pathway activation-
based subgroups of patients with lung cancer. Group A was 
composed of only two adenocarcinoma cases and was char-
acterized by the activation of growth-factor–driven signaling, 
namely activation of ERBB2 and ERBB3, platelet-derived 
growth factor receptor, vascular endothelial growth fac-
tor receptor (VEGFR), and a large number of known linked 
downstream cytoplasmic signaling networks such as AMPK, 
phosphoinositide 3-kinase- mammalian target of rapamycin 
(PI3K)-mTOR, JAK-STAT, and extracellular signal-regulated 
kinase (ERK) signaling modules. Group B was underpinned 
by AKT network activation and increased relative Cyclin D1 
expression. Group C contained tumors that shared ERBB2-
3–based signaling, increased ERBB4 along with activation of 
SMAD signaling, and Notch homolog 1 (NOTCH) signaling 
and increased relative expression of autophagy proteins such 
as Beclin. Group D was dominated by high relative levels of 
proapoptosis proteins such as nearly all cleaved Caspases mea-
sured3,7,9 and cleaved PARP along with increased expression 
TABLE 1.  Patient Characteristics of Tissue Study Set 
Primary Lung Cancer Samples
No of Patients Total
Female 11
Male 36
Histological subtype
Adenocarcinoma 27
Squamous 20
T stage
T1 24
T2 20
T3 3
N stage
N0 28
N1 14
N2 4
NX 1
Tumor grade
GX 4
G1 7
G2 25
G3 11
Months of survival
<31 23
>31 24
Status
Died 38
Alive 9
Age mean at diagnosis (yr) 66 (48–85)
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and/or activation of EGFR receptor family, namely EGFR, 
ERBB3, and ERBB4. Other important tryrosine kinase mol-
ecules were activated in group D such as IGFR and RET and 
ACK. Finally, group E showed a systemic activation of nearly 
all signaling networks measured, except for ERBB2- and 
ERBB3-driven signaling, which was comparably lower. These 
pathway activation mapping results indicate that NSCLC 
seems to segregate into distinct pathway-driven molecular 
phenotypes each with a unique molecular signature and shed 
further light on the molecular heterogeneity of the disease. 
However, because some of these subgroups (e.g., subgroup 
A) are composed of a small number of patients, further vali-
dation of these pathway modules is absolutely necessary to 
determine significance and verification of these cohorts.
To fully elucidate the nature of the molecular heteroge-
neity, we explored the extent of differences in the protein sig-
naling architecture between the two major histological types 
of NSCLC, adenocarcinoma and squamous cell lung can-
cers. Mean comparison analysis (Table 2) between squamous 
and adenocarcinoma groups revealed 26 proteins differently 
expressed between the two types (p < 0.05). Interestingly, a 
large majority of these proteins were more highly activated 
in squamous compared with the adenocarcinoma cases. 
Only two proteins, total ERBB3/HER3 and protein kinase C 
(PKC) alpha/beta II T638/641, had higher intensity levels in 
adenocarcinomas compared with squamous carcinomas. The 
analysis revealed a systemic EGFR-AKT pathway activation 
in squamous cell carcinomas compared with adenocarcino-
mas, with increased phosphorylation of EGFR, ERBB3, and 
a large number of AKT substrates (BCL2-associated agonist 
of cell death [BAD], forkhead homolog in rhabdomyosarcoma 
[FOXO1], forkhead homolog in rhabdomyosarcoma /forkhead 
box O3 [FOXO1/O3], proline-rich Akt-substrate 1 [PRAS40], 
eukaryotic translation initiation factor 4E binding protein 1 
[4E-BP1], cyclin-dependent kinase inhibitor 1B [p27], and 
glycogen synthase kinase 3 [GSK3]).
On the basis of these results, we next explored more spe-
cifically the signaling aspects of the EGFR and AKT-mTOR 
networks within squamous and adenocarcinomas, leveraging 
the multiplexed nature of the reverse phase protein microarray 
(RPMA) format. Unsupervised hierarchical clustering analy-
sis (Fig. 2A) of total EGFR and seven independent phosphor-
ylation sites of the receptor (Y1173, Y1148, Y1068, Y992, 
Y845, Y1045, S1046/1047) revealed that the EGFR signaling 
architecture clustered into four major groups. These group-
ings were characterized by overt lack of EGFR protein and 
concomitant lack of EGFR activation at any site (group 1), or 
high expression of EGFR protein along with EGFR activation/
FIGURE 1.  Protein pathway activa-
tion map of NSCLC by unsupervised 
hierarchical clustering. A, Clustering 
analysis of 128 signaling proteins (x 
axis) whose activation/expression lev-
els determined by RPMA are shown 
for all 47 patient tumor samples 
obtained by LCM (y axis). The five 
major pathway-driven subgroups A–E 
are highlighted. Squamous tumors 
are shown in red and adenocarci-
noma tumors in black (y axis). In the 
map, red is highest relative level of 
expression/activation, black is mean 
values, and green is lowest rela-
tive level of expression/activation. 
B, Clustering analysis as in Panel 
A except average values for each 
protein/phosphoprotein within each 
of the five subgroups were used. 
NSCLC, non–small-cell lung cancer; 
LCM, laser capture microdissection.
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phosphorylation (group 2), low or absent total EGFR yet rela-
tively high levels of EGFR activation/phosphorylation at one 
or more of the seven sites measured (group 3), and high levels 
of EGFR protein and high levels of phosphorylation of EGFR 
at nearly all of the seven phosphorylation sites measured 
(group 4). This analysis revealed the molecular heterogene-
ity of EGFR signaling in NSCLC, and that there is a subset 
of patients with NSCLC that harbor low EGFR yet relatively 
high levels of receptor activation (group 3). However, the dis-
tribution of adenocarcinoma (black label, Fig. 2A) and squa-
mous NSCLC (red label, Fig. 2A) was fairly even among the 
signaling clusters. In keeping with the statistical analysis that 
revealed increased activation of EGFR and AKT-mTOR in 
squamous cell carcinomas, of the four subgroups identified 
based on EGFR signaling (Fig. 2 A), the one subgroup (sub-
group 1) that is characterized by lack of EGFR expression and 
EGFR signaling/phosphorylation is composed of a majority 
of adenocarcinomas (9 of 11, 82%). Moreover, the signaling 
subgroups were underpinned neither by a statistically signifi-
cant association with nodal status nor by EGFR mutational 
status (data not shown).
Pathway activation mapping of the AKT-mTOR 
signaling axis, whereby activation of AKT, mTOR, 4EBP1, 
p70S6K, and eIF4G was measured, revealed three overarching 
subgroups of activation (Fig. 2B). The results showed both 
TABLE 2.  Statistically Significant Analytes Squamous versus 
Adenocarcinoma NCLC 
Proteins/Phosphoproteins p.Value
Expression/
Activation Trend
PKCalpha/betaII (T638/641) 0.0296 S▼
ERBB3/HER3 0.0002 S▼
FOXO1 (T24)/FOXO3a (T32) 0.0003 S▲
LKB1 S334 0.0023 S▲
4E-BP1 T70 0.0042 S▲
PRAS40 T246 0.0052 S▲
p27 T187 0.0058 S▲
Akt S473 0.0062 S▲
PKC zeta/lamda (T410/403) 0.0091 S▲
ACK1 Y284 0.0093 S▲
Src Family Y416 0.0112 S▲
MST1 (T183)/MST2 (T180) 0.0131 S▲
SMAD1(S/S)/SMAD5(S/S)/SMAD8(S/S) 0.0174 S▲
Total EGFR 0.0174 S▲
AURORA A (T288)/B (T232)/C (T198) 0.0174 S▲
GSK3 alpha-beta S21/9 0.0235 S▲
BAD S136 0.0002 S▲
PKC theta T538 0.0412 S▲
FOXO1 S256 0.0491 S▲
FIGURE 2.  NSCLC EGFR signaling analysis. A, Clustering analysis of total EGFR and seven EGFR phosphorylation sites signal-
ing proteins (in order from left to right: S1046/1047, Y845, Y1045, Y992, Y1068, Y1148, Y1173,) (x axis) whose activation/
expression levels determined by RPMA are shown for all 47 patient tumor samples obtained by LCM (y axis). The four major 
pathway-driven subgroups1–4 are highlighted. Squamous tumors are shown in red and adenocarcinoma tumors in black (y 
axis). In the map, red is highest relative level of expression/activation, black is mean values, and green is lowest relative level 
of expression/activation. B, Clustering analysis of AKT-mTOR pathway network, showing three major cohorts (groups 1–3). 
Pathway activation analytes on x axis from left to right: 4EBP1 (S65), mTOR (S2448), mTOR (S2481), p70 S6 (S371), eIF4G 
(S1108), 4EBP1 (T70), p70 S6 (T389), AKT (S473), AKT (T308). NSCLC, non–small-cell lung cancer; LCM, laser capture  
microdissection; 4E-BP1, eukaryotic translation initiation factor 4E binding protein 1; mTOR, mammalian target of rapamycin; 
AKT, v-akt murine thymoma viral oncogene homolog 1.
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AKT and mTOR networks having high relative activation 
(group 1), mainly mTOR pathway activation (group 2), or 
neither pathway significantly activated (group 3). In keeping 
with the statistical results that revealed increased relative levels 
of AKT-mTOR pathway signaling proteins in squamous cell 
NSCLC compared with adenocarcinomas, the AKT-mTOR 
pathway activation subgrouping analysis (Fig. 2 B) revealed 
that a majority (14 of 23, 61%) of the AKT-mTOR pathway 
negative subgroup (subgroup 3) were adenocarcinomas, and 
75% (3 of 4) of the highly activated AKT-mTOR samples in 
subgroup 2 were squamous cell NSCLC tumors. These results 
support those seen for EGFR network activation, namely 
that NSCLC is composed of distinct, yet heterogeneous, 
subgroups underpinned by pathway activation differences. 
Generally, AKT activation was seen concomitant with mTOR 
pathway activation, which is known to lie downstream of AKT. 
No statistically significant correlation with EGFR mutation 
status was seen with AKT-mTOR activation/phosphorylation 
subgroups (data not shown).
Protein Pathway Activation Mapping 
of Node-Negative NSCLC
Although the signaling architecture of pathways that 
underpin important current molecular targets for NSCLC 
such as EGFR, AKT, and mTOR provide evidence of distinct 
heterogeneity that has implications for therapeutic stratifica-
tion and response to these therapies, of critical importance in 
the management of lung cancer is the identification of patients 
with node-negative disease, who have aggressive tumors. Our 
study set of tumors contained 28 N0 tumors of both adenocar-
cinoma (n = 18) and squamous (n = 9) carcinoma lineage, and 
this set provided a unique opportunity to determine whether 
any protein signaling network(s) correlated with overall sur-
vival (OS). As shown in Table 3, using a median OS value of 
31 months as a cutpoint for short- versus long-term survival 
for 27 N0 patients from whom the OS data were obtained, 
RPMA analysis revealed 65 signaling analytes that were sig-
nificantly more highly activated/phosphorylated in the short-
term OS N0 cases (n = 11; range, 2–31 months, median 9 
months) versus long-term OS (n = 16; range, 31–120 months, 
median 90 months). Unsupervised clustering analysis of 
the data reveals, as expected, near complete segregation of 
the short-term OS from long-term OS node-negative group 
(Fig. 3) with the notable high systemic activation/phosphory-
lation of many of the signaling proteins seen.
On the basis of this observation, an optimal cutpoint 
of 2.8 relative units based on a protein pathway activation 
signature was calculated using a combination of normalized 
and scaled relative intensity values of the 65 analytes shown 
in Table 3. The optimal cutpoint was determined by receiver 
operating characteristic curve analysis, which gave a sensitivity 
of 91% (10 of 11) and specificity of 88% (14 of 16) for 
distinguishing short-term (median 9 months) from long-term 
(median 90 months) survival in the 27 N0 patient population 
from which the OS was known. The score was determined by 
first normalizing the relative intensity values of each of the 
65 analytes that were increased in patients with N0 and short-
term survival. Within each analyte, the intensity value of every 
TABLE 3.  Statistically Significant Analytes for N0 NSCLC 
with Short-Term Survival 
Proteins No p Value
4E-BP1 S65 0.0394
4E-BP1 T70 0.0462
Acetil CoA Carb S79 0.0256
Adducin S662 0.0049
Akt S473 0.0849
AMPK alpha1 S485 0.0041
AMPK beta1 S108 0.0286
Aurora A (T288)/B (T232)/C (T198) 0.0107
Bad S112 0.0057
Bad S136 0.0035
Bad S155 0.0228
B-Raf S445 0.0273
c-Abl T735 0.0049
c-Abl Y245 0.0343
CC9 D330 0.0122
Chk1 S345 0.0273
c-KIT Y719 0.0128
cPLA2 (S505) 0.031
CREB S133 0.0162
EGFR Y1148 0.0497
EGFR Y1173 0.0097
eIF4E S209 0.0452
eIF4G S1108 0.0179
ErbB3 Y1197 0.0273
ErbB3 Y1289 0.035
FADD S194 0.0057
FAK Y576/577 0.0185
FoxO1/3a T24/32 0.0029
FoxO3A S253 0.0047
FoxO1 S256 0.0003
GSK3 alpha-beta S21/9 0.0041
Jak1 Y1022/1023 0.0538
LIMK1 T508/LIMK2 T505 0.0161
LKB1 S334 0.0241
MARCKS S152/156 0.0011
MEK1/2 S217/221 0.014
MSK1 S360 0.0043
mTOR S2448 0.0106
p27 T187 0.0101
p38 MAPKinase (T180/Y182) 0.0078
PAK1(S199/204)/PAK2(S192/197) 0.0426
PAK1T423/PAK2T402 0.0122
PKC theta T538 0.0011
PKC zeta/Lamda (T410/403) 0.0049
PLCgamma1 Y783 0.0114
PLK1 T210 0.0248
PRAS40 T246 0.0001
Pyk2 Y402 0.0014
Raf S259 0.0139
Ras-GRF1 (S916) 0.031
(Continued)
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sample was divided by the highest patient’s value within the 
entire cohort of 65 patients. Normalized intensity values of 
each analyte were then summed for every patient. Thus, the 
final pathway signature score did not weigh any significant 
endpoint as more important than another. Cox proportional 
hazard model analysis of the data (Table 4) revealed that only 
the pathway signature score (p = 0.0001) and histology for 
adenocarcinoma (p = 0.01) had statistical significance for OS 
compared with other clinical variables measured, including 
nodal status, sex, grade, site, and stage. Because only four 
of the 27 N0 patients harbored an EGFR mutation, statistical 
correlation with OS was not determined.
Characterization of the underpinning repertoire of 
the statistically significant activated proteins that comprised 
the aggressive signature revealed a large number of recep-
tor tyrosine kinases (RTK), EGFR family members, with 
multiple independent phosphorylation sites on a number of 
the receptors that were measured (EGFR (Y1173), (Y1148), 
and (Y845); ERBB3 (Y1289) and (Y1197); VEGFR (Y996), 
(Y951), and (Y1175); c-KIT Y7194). Concomitantly, many 
other proteins known to be downstream in RTK/growth factor–
driven cellular signaling pathways were coordinately activated. 
In particular, the hierarchical clustering analysis revealed the 
combined expression of many proteins that belonged to the 
AKT signaling pathway, including AKT (S473), GSK3αβ 
(S21/9), PRAS40 (T246), multiple forkhead family members 
FOXO1/3A (T24/32), FOXO3A S253, FOXO1 S256, along 
with BAD (S155, S136, and S112) and p27 (T187), TSC2 
(Y1571) as well as collateral mTOR networks (mTOR (S2448), 
4EBP1 (S65 and T70)). Other linked networks seen coordi-
nately activated in aggressive N0 tumors at multiple nodes 
were the AMPK signaling pathway (AMPK α (S485), AMPK 
β (S108), ACC (S79), LKB1 (S334)), SMAD signaling, path-
ways regulating motility and adhesion (e.g., FAK (Y576/577), 
LIMK 1/2 (T508/T505)), and the JAK-STAT pathway (JAK1 
(Y1022/1023), STAT3 (S727), and STAT5 (Y694)).
The coordinate nature of the activated kinase-substrate 
linkage within the signaling architecture of aggressive N0 
TABLE 3.  (Continued)
Proteins No p Value
Smad1(S/S)/Smad5(S/S)/Smad8(S/S) 0.0168
Smad2 S245/250/255 0.0037
Smad2 S465/467 0.0443
Src Family Y416 0.0014
Src Y527 0.0162
ST6GALNAC5 0.0885
Stat3 S727 0.0055
Stat5 Y694 0.0185
Tuberin/TSC2 Y1571 0.0088
VEGFR Y996 0.0016
VEGFR2 Y1175 (19A10) 0.0018
VEGFR2 Y951 0.0001
FIGURE 3.  Clustering analysis of protein signaling architecture in node-negative NSCLC. Proteins from Table 4 were 
used in unsupervised hierarchical clustering analysis of 27 tumors from patients with N0 NSCLC. Patients with short-term 
survival (median OS = 9 months) are shown in blue (y axis) and long-term survival (median OS = 90 months) in green. 
Phosphoproteins/proteins are shown on the x axis. In the map, red is highest relative level of expression/activation, black is 
intermediate values, and green is lowest relative level of expression/activation. White line is shown that segregates the two clus-
ters formed. NSCLC, non–small-cell lung cancer.
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tumors is visually revealed in Fig. 4, where a selection of the 
independent statistically significant nodes within the RTK-
AKT pathway was mapped to a signaling diagram (repro-
duced courtesy of Cell Signaling, Inc., www.cellsignal.com). 
For each of the five interconected signaling pathway protein 
nodes selected, independent Kaplan–Meier plots are shown 
for N0 patients whose tumors have relative phosphorylation/
activation levels above (HIGH, in blue) or below (LOW, in 
red) the median level of the selected analyte across the study 
set population. The data reveal both the nature of the discrimi-
nation achieved by the specific individual protein activation 
and the interlinked nature of the data, which indicates a coor-
dinate activation of the pathways in patients with N0 disease 
and an aggressive intrinsic phenotype.
DISCUSSION
A broadscale analysis of the functional protein signal-
ing architecture of NCSLC, quantitatively measuring 128 key 
signaling proteins concomitantly, revealed the presence of 
distinct molecular subgroups underpinned by distinct inter-
linked signaling pathways and at the same time displaying 
unique patient-specific signaling heterogeneity. Such path-
ways are revealed because we are measuring enzymatically 
driven protein phosphorylation as direct read-out of the pre-
ceding kinase-phosphatase activity. This activity is based 
on the aggregate of pathway use in asynchratic tissue cells 
whose combined snapshots in time provide a window into 
the ongoing signaling activity. The results showed that the 
overall signaling profiles of squamous and adenocarcinoma 
tumors seemed to co-mingle, although the two were com-
posed of distinct underpinning signaling motifs. A deeper 
investigation into EGFR signaling cascades identified unique 
molecular subgroups of an EGFR-low/pEGFR-high cohort 
and an EGFR-high/pEGFR-low cohort of NSCLC. Last, 
pathway activation mapping analysis identified biochemi-
cally interlinked RTK-driven protein pathways that could dis-
tinguish N0 patients with short-term OS (median 9 months) 
from long-term (median 61 months) survival. Analysis of 
the AKT-mTOR pathway activation network also revealed 
distinct molecular subgroups of activation with both con-
comitant linked activation of AKT and mTOR signaling and 
independent activation of either module.
The study used a protein microarray–driven platform, 
the RPMA, which has been extensively used by us in other 
analyses of human malignancies,45–47 to perform the most 
comprehensive mapping of the protein signaling architec-
ture of human NSCLC clinical specimens to date. The study 
set used a collection of frozen specimens that were carefully 
chosen based on the control of preanalytical variables such 
as sample collection, handling, storage, and time-to-freezing 
after surgical removal. Furthermore, based on past evidence 
that upfront cellular enrichment is required for accurate pro-
tein measurement/activation determination of cellular tissue 
compartments,46,48 we used LCM to significantly enrich for 
tumor epithelium (>95% purity based on pre- and post-LCM 
microscopic visualization) as the cellular input for all analysis.
The combination of these efforts has produced an impor-
tant preliminary data set that will require much further efforts 
to verify the signaling subtypes identified, and the pathway 
activation found in tumors from patients with node-negative 
disease who have poor OS. Despite the powerful methodol-
ogy used combined with the LCM enrichment techniques, the 
study set used comprised too small a number (47 cases) to 
generate final conclusive data about what pathway activation 
phenotypes underpin NSCLC and aggressive protein pathway 
activation signatures. However, on the basis of methodologi-
cal workflow used, we expect that this pilot data can be con-
fidently used as a launch-point for further hypothesis-driven 
analysis and verification of the results herein. Moreover, 
although the signaling analysis was extensive, the full rep-
ertoire of the human kinome was certainly not surveyed and 
many specific signaling proteins were not queried, and a 
number of important signaling pathways untested. We fully 
expect that even further coverage of the signal transduction 
machinery will yield new discoveries. However, our rationale 
for this study was to select key signaling proteins known to be 
involved in tumorigenesis and metastasis, regulating growth 
and energy metaboism, survival, apoptosis, differentiation, 
motility, and inflammation and which were key surrogates and 
direct targets for the many kinase inhibitors that populate cur-
rent phase I–III clinical trial pipeline. Furthermore, although 
signaling can be regulated by a number of post-translational 
modification–driven events (e.g., glycosylation and acetyla-
tion), we chose to study these proteins at the functional level 
by measuring protein phosphorylation (the principal regulator 
of signal transduction and the key analyte endpoint for the 
recording of ongoing cellular kinase activity) so that we could 
generate a direct knowledge snapshot of the ongoing signal-
ing cascades within the tumor cells. Moreover, we postulate 
TABLE 4.  Cox Proportional Analysis 
Characteristic Cases Deaths
Median 
Survival 
(mo)
p-Value 
Log-Rank 
Test
Sex
 Male 20 15 42
 Female 7 5 42 0.99
Age (yr)
 <70 16 12 42
 ≥70 11 8 33 0.56
Pathway activation signature
 0 11 11 9
 1 16 9 90 0.0001
 T
 1 18 13 46
 2–3 9 7 9 0.27
Grade
 1 5 4 42
 2 15 10 54
 3 7 6 15 0.18
Histology
 Squamo 9 8 15
 Adeno 18 12 63 0.01
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that we are able to identify signaling derangements even in 
unmeasured individual signaling proteins based on the fact 
that we are measuring many of the key principal “hub” loca-
tions within the signaling architecture which integrate signal-
ing activation from a multitude of inputs.
Past and recent work involving the analysis of NSCLC 
using both genomic and proteomic approaches has found 
evidence for molecular heterogeniety and distinct cohorts of 
patients underpinned by specific gene expression and pro-
tein expression differences.8–15 Recent signaling analysis of 
NSCLC clinical samples using a much smaller number of 
phosphoprotein endpoints than what was used in this study 
found that tumor signaling portraits could be accurately dis-
tinguished from matched normal tissue and that energy-sens-
ing signaling networks correlated with recurrence.16
Our analysis indicated that the signaling architecture 
of NSCLC makes it highly amenable to targeted therapy-
based inhibition and consideration of new combinations of 
therapeutics. We identified distinct cohorts of patients whose 
tumor portraits contained relatively high levels of activation 
of RTKs such as platelet-derived growth factor receptor, 
EGFR concomitant with ERBB2 and ERBB3 activation, 
along with RET and ACK, and downstream pathway acti-
vation through cytoplasmic signaling such as AKT-mTOR, 
RAS-ERK, and JAK-STAT activation. Although it is not 
known at this time whether the activation levels are driven 
by activating mutations or exogenous receptor-ligand sig-
naling cascades and tumor-stroma interactions, therapeutic 
targeting, and modulation of the activation could test the 
causal role the high levels of pathway activation have in each 
patient tumor.
The identification of cohorts of patients with NSCLC 
with relatively high and low levels of total receptor proteins 
such as EGFR, yet disconcordant phosphorylation levels of 
the same protein, could be clinically important if validated 
in further study sets. Although identification of patients who 
respond to EGFR inhibitors based on mutational analysis and 
alternate pathway activation has been a poster child for phar-
macogenomics,31–41 recent reports indicate that mutational 
status may be accurately predicted by EGFR phosphorylation 
FIGURE 4.  Activated c-erbB3-AKT signaling network in node-negative NSCLC correlates with poor overall survival. A focused 
analysis of five biochemically linked signaling proteins (ERBB3, PRAS40, FOXO1, GSK3, and AKT) found within the overarching 
protein activation signature shown in Figure 3 is shown using a signaling cartoon of AKT signaling network (reproduced cour-
tesy of Cell Signaling Technology, Inc., www.cellsignal.com) along with the individual statistically significant KM plots (ERBB3: 
p = 0.0089; PRAS40: p < 0.0001; FOXO1: p = 0.0006; GSK3: p = 0.0125; and AKT: p = 0.089) of each phosphoprotein shown 
numbered in the map. For the KM plots, red shows low levels of activation of the cognate protein and blue shows high relative 
phosphorylation levels (median intensity value of each protein was used as the cutpoint for statistical analysis). ERBB3, ; PRAS40, ;  
FOXO1, ; GSK3, ; AKT, ; NSCLC, non–small-cell lung cancer; KM, Kaplan–Meier.
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patterns, especially Y1068 and Y104515,49 and Y1173,42 and 
thus, protein phosphorylation profiling of EGFR may pro-
vide a new companion diagnostic assay method for selection 
and stratification for therapy.50 Development of quantitative 
approaches to measure EGFR phosphorylation, such as by 
RPMA, can be used to identify optimal cutpoints for molecu-
lar correlates, and a more comprehensive quantitative survey 
of the many EGFR phosphorylation sites (we measured seven 
different sites) along with downstream signaling analysis 
through AKT and ERK could yield better response predic-
tion to EGFR inhibitors. The fact that AKT and mTOR path-
way activation were found in patient subgroups in which both 
modules were activated simultaneously or alone indicates the 
potential to stratify patients for combination therapeutics that 
target PI3K-AKT and downstream mTOR together, or PI3K 
and mTOR inhibitors alone.
Identification of patients with early-stage NSCLC, 
who have aggressive tumors that are predestined to a more 
rapid disease progression would be of critical importance, 
especially those patients with N0 disease who are mostly 
left untreated after surgery. These patients could be strati-
fied to more aggressive paths of treatment and monitoring. 
Thus, pathway activation mapping provides data that could 
extend utility beyond prognostic signatures of recurrence and 
progression as has been done by mRNA and miRNA profil-
ing51–55 and provides data that could rationally specify the 
best therapies that would work to mitigate the rapid course 
of the disease in N0 patients with the most aggressive disease 
course. Our preliminary finding points to a systemic activation 
of interlinked pathway networks in patients with aggressive 
N0 disease composed of a number of important drug targets. 
Members of the AMPK-LKB1 pathway, vascular epidermal 
growth factor receptor (VEGFR), EGFR/ERBB3, PTK2B 
protein tyrosine kinase 2 beta- focal adhesion kinase (PYK2-
FAK), aurora kinase A (AURORA) and polo-like kinase 1 
(PLK1), and JAK-STAT, concomitant with many members 
of the AKT-mTOR downstream signaling modules, which 
integrate these upstream activating events, were all found sys-
temically activated in these aggressive tumors. Each of these 
is under intense investigation for the development of targeted 
therapy inhibitors, so this signature, if validated in larger inde-
pendent study sets, could form the basis not only for prog-
nostic determination but also for clinicians so that they have 
an armamentarium of molecularly targeted inhibitors to use 
for these patients in prospective clinical trials. This signature 
was based on a single pilot study and would require much 
further verification in independent study sets to understand 
any potential clinical significance. However, some of the mol-
ecules we identified in the aggressive signature have also been 
recently reported as being implicated in aggressive early-stage 
NSCLC and patients with NSCLC with worse overall out-
come, which, although not minimizing the existing need for 
independent validation, does provide some level of confidence 
to the overall fidelity of our initial findings. Analysis of 134 
patients with resected stage IA–IIB NSCLC revealed that total 
levels of mTOR protein as measured by immunohistochem-
istry (IHC) were significantly higher in those patients with 
node-negative or stage IA disease who had poor outcome.56 
Proteomic analysis of recurrent node-negative tumors identi-
fied activation of AMPK and adhesion molecules.13 Analysis 
by IHC of FoxM1 total protein levels from squamous cell 
NSCLC revealed a statistical correlation with outcome and 
an aggressive clinical course.57 Recently, it was reported that 
patients with NSCLC whose tumors had high relative levels 
of AKT phosphorylation and loss of PTEN expression showed 
significantly worse 5-year survival rates,58 and that increased 
levels of phosphorylated eIF4E are associated with survival 
through AKT pathway activation in NSCLC.59 Interestingly, 
we found that activation/phosphorylation of multiple SMAD 
family members (SMAD1/5/8 and SMAD2) was increased in 
patients with N0 tumors and poor survival. Given the dichoto-
mous nature of transforming growth factor–driven signaling,60 
our preliminary evidence that activation of SMAD signaling 
occurs in patients with early-stage, node-negative lung cancer 
with short survival warrants further investigation.
Although the causal significance of the pathway activa-
tion modules identified in this initial survey of the pathway 
activation architecture of NSCLC remains unknown, we hope 
that this initial survey will serve as a beginning for mapping 
signaling events in clinical specimens that could be used to 
rationally decide on targeted therapy choices and even priori-
tize combinations of therapeutics.61,62 Because our analysis did 
not include chemoresponse or targeted therapy prediction, our 
results are limited to molecular characterization of underpin-
ning signaling network architecture. Because the architecture 
provided by the RPMA is focused around druggable targets 
in purified NSCLC tumor epithelium, it is our hope that this 
inaugural data set will form the basis by which predictive 
marker analysis/discovery could occur within the context of 
chemo/targeted therapeutic response. Moreover, our ongoing 
validation work in larger independent tumor sets where both 
chemo/targeted therapies were used and outcomes known, 
will provide the basis for selection and ranking those base-
line signaling networks that will be chosen for further analysis 
in both animal models for functional workup and prospective 
clinical assay development for personalized medicine-based 
opportunities.
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